Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Status:
Not yet recruiting
Trial end date:
2027-01-03
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil
in combination with temozolomide and/or radiation therapy (standard of care) in treating
patients with glioblastoma. Mycophenolate mofetil is an immunosuppressant drug that is
typically used to prevent organ rejection in transplant recipients. However, mycophenolate
mofetil may also help chemotherapy with temozolomide work better by making tumor cells more
sensitive to the drug. The purpose of this trial is to determine if mycophenolate mofetil
combined with temozolomide can stop glioblastoma.